Diagnostic performance of the Elecsys SARS-CoV-2 antigen assay in the clinical routine of a tertiary care hospital: Preliminary results from a single-center evaluation.

Abstract

BackgroundThis report describes a manufacturer‐independent evaluation of the diagnostic accuracy of the Elecsys SARS‐CoV‐2 antigen assay from Roche Diagnostics in a tertiary care setting.MethodsIn this single‐center study, we used nasopharyngeal swabs from 403 cases from the emergency department and intensive care unit of our hospital. The reference standard for detecting SARS‐CoV‐2 was the reverse‐transcription polymerase chain reaction (RT‐PCR) assay. Cycle threshold (Ct) values were recorded for positive RT‐PCR assays. The index test was the Elecsys SARS‐CoV‐2 antigen assay. This electrochemiluminescence immunoassay produces results as cutoff index (COI) values, with values ≥1.00 being reported as positive.ResultsOf the 403 cases, 47 showed positive results in RT‐PCR assays. Of the 47 RT‐PCR‐positive cases, 12 showed positive results in the antigen assay. Of the 356 RT‐PCR‐negative cases, all showed negative results in the antigen assay. Thus, the antigen assay showed a sensitivity of 26% (95% CI, 14%‐40%) and specificity of 100% (95% CI, 99%‐100%). Analysis of the relationship between Ct values and COI values in the 47 RT‐PCR‐positive cases showed a correlation coefficient of −0.704 (95% CI, −0.824 to −0.522). The true‐positive rate of the antigen assay for Ct values of 15–24.9, 25–29.9, 30–34.9, and 35–39.9 was 100%, 44%, 8%, and 6%, respectively.ConclusionsThe Elecsys SARS‐CoV‐2 antigen assay has a low sensitivity for detecting SARS‐CoV‐2 from nasopharyngeal swabs. Hence, we decided to not use this assay in the clinical routine of our hospital.